MRK - Dosing underway in ALX Oncology/Merck's mid-stage ASPEN-04 study for head and neck cancer

ALX Oncology Holdings (ALXO) in partnership with Merck (MRK) announce the first patient has been dosed in the Phase 2 ASPEN-04 study evaluating the combination of ALX148, a next generation CD47 blocker, with Keytruda (pembrolizumab), an anti-PD-1 therapy, and standard chemotherapy for the treatment of patients with advanced head and neck squamous cell carcinoma ((HNSCC)). This study will enroll patients regardless of PD-L1 expression status and is based on promising clinical data from ASPEN-01 Phase 1 study.

For further details see:

Dosing underway in ALX Oncology/Merck's mid-stage ASPEN-04 study for head and neck cancer